Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

DNDeedra NicoletNANajla Al AliAAAlexander J. Ambinder

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows similar survival with intensive chemotherapy and venetoclax plus hypomethylating agents in older AML patients, indicating treatment response varies by risk classification.

Key Points

  • To compare treatment response and survival for older AML patients receiving intensive chemotherapy versus venetoclax with hypomethylating agents, based on ELN risk stratifications.
  • Analyzed clinical and molecular data from 711 AML patients across 11 institutions.
  • Compared treatment response between patients receiving intensive chemotherapy and those receiving VEN/HMA.
  • Used statistical tests including Chi-square and Kaplan-Meier methods for analyzing overall survival.
  • Median overall survival was 18 months for intensive chemotherapy vs. 15.6 months for VEN/HMA.
  • Complete remission was higher in the intensive chemotherapy group (66% vs 54%).
  • Survival was similar across treatment types for patients with intermediate and adverse risk disease.

Cite This Study

Nicolet et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d891https://doi.org/10.1182/blood-2025-5157
View Full Paper
Ask AI
Bookmark
Share